Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells

Oncogene

Volumn 25, Issue 14, 2006, Pages 2011-2021

  Gong, J ^a   Zhu, J ^a   Goodman Jr , O B ^a   Pestell, R G ^b   Schlegel, P N ^a   Nanus, D M ^a   Shen, R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Acetylation; Androgen receptor; Androgen independent prostate cancer; Bombesin; Neuropeptides; p300

Indexed keywords

AMINO ACID; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; GROWTH FACTOR; HISTONE ACETYLTRANSFERASE; MEMBRANE METALLOENDOPEPTIDASE; NEUROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C DELTA; PROTEIN KINASE C INHIBITOR; PROTEIN P300; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA;

ACETYLATION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ACETYLATION; BLOTTING, WESTERN; BOMBESIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; ENZYME ACTIVATION; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN KINASE C-DELTA; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 33645520881     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209231     Document Type: Article

References (49)

1. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. (1998). Prostate 8: 52-61.
2. Aprikian AG, Tremblay L, Han K, Chevalier S. (1997). Int J Cancer 72: 498-504.
3. Bologna M, Festuccia C, Muz P, Biordi L, Ciomei M. (1989). Cancer 63: 1714-1720.
4. Borre M, Nerstrom B, Overgaard J. (2000). Clin Cancer Res 6: 1882-1890.
5. Bouras T, Fu M, Sauve AA, Wang F, Quong AA, Perkins ND et al. (2005). J Biol Chem 280(11): 10264-10276.
6. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y et al. (1999). J Natl Cancer Inst 91: 1758-1764.
7. Chan HM, La Thangue NB. (2001). J Cell Sci 114: 2363-2373.
8. Chim CS, Wong ASY, Kwong YL. (2004). Cancer Genet Cytogenet 150: 164-167.
9. Cui Y, Zhang M, Pestell RG, Curran EM, Welshons WV, Fuqua SAW. (2004). Cancer Res 64: 9199-9208.
10. Culig Z, Hobisch A, Bartsch G, Klocker H. (2000). Microsc Res Tech 51: 447-455.
11. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trampman J, Hittmair A et al. (1994). Cancer Res 54: 5474-5478.
12. Culig Z, Klocker H, Bartsch G, Hobisch A. (2002). Endocr Relat Cancer 9: 155-170.
13. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC et al. (2002). Clin Cancer Res 8: 2399-2405.
14. Darne C, Vessiere G, Jean C. (1998). European J Biochem 256: 541-549.
15. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. (2005). Cancer Res 65: 5965-5973.
16. Debes JD, Schmidt LJ, Huang H, Tindall DJ. (2002). Cancer Res 62: 5632-5636.
17. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DAL, Tindall DJ. (2003). Cancer Res 63: 7638-7640.
18. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D et al. (2003). Mol Cell Biol 23: 8563-8575.
19. Fu M, Rao M, Wu K, Wang C, Zhang X, Hessien M et al. (2004a). J Biol Chem 279(9): 29436-29449.
20. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L et al. (2000). J Biol Chem 275: 20853-20860.
21. Fu M, Wang C, Wang J, Zafonte B, Lisanti MP, Pestell RG. (2002a). Cytokine Growth Factor Rev 13: 259-276.
22. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG et al. (2002b). Mol Cell Biol 22: 3373-3388.
23. Fu M, Wang C, Zhang X, Pestell RG. (2004b). Biochem Pharmacol 68: 1199-1208.
24. Fu M, Wang CG, Rao M, Wu X, Bouras T, Zhang X et al. (2005). J Biol Chem 280: 29728-29742.
25. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. (2002). J Biol Chem 277: 25904-25913.
26. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF et al. (2000). Nat Genet 24: 300-303.
27. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD et al. (2002). J Biol Chem 277: 29304-29314.
28. Giordano A, Avantaggiati ML. (1999). J Cell Physiol 181: 218-230.
29. Heinlein CA, Chang C. (2002). Endocr Rev 23: 175-200.
30. Kang Z, Janne OA, Palvomo JJ. (2004). Mol Endocrinol 18: 2633-2648.
31. Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R et al. (1999). J Mol Endocrinol 22: 313-325.
32. Kitabayashi I, Eckner R, Arany Z, Chiu R, Gachelin G, Liverston DM et al. (1995). EMBO J 14: 33496-33509.
33. Lee LF, Guan J, Qiu Y, Kung HJ. (2001). Mol Cell Biol 21: 8385-8397.
34. Levine L, Lucci III JA, Pazdrak B, Cheng JZ, Gu YS, Townsend Jr CM et al. (2003). Cancer Res 63: 3495-3502.
35. McKenna NJ, Lanz RB, O'Malley BW. (1999). Endocr Rev 20: 321-344.
36. Papandreou CN, Usmani B, Geng YP, Bogenrieder T, Freeman RH, Wilk S et al. (1998). Nat Med 4: 50-57.
37. Sadar MD, Hussain M, Bruchovsky N. (1999). Endocr Relat Cancer 6: 487-502.
38. Schwartz C, Beck K, Mink S, Schmolke M, Budde B, Wenning D et al. (2003). EMBO J 22: 882-892.
39. Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B et al. (2000). Mol Cell Endocrinol 170: 131-142.
40. Shigeno K, Yoshida H, Pan L, Luo JM, Fujisawa S, Naito K et al. (2004). Cancer Lett 213: 11-20.
41. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T et al. (2001). Cancer Res 61: 3294-3298.
42. Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D, Nanus DM.. (2000a). Cancer Res 60: 6590-6596.
43. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D et al. (2000b). J Clin Inv 106: 1399-1407.
44. Vashchenko N, Abrahamsson PA. (2005). Eur Urol 47: 147-155.
45. Vo N, Goodman RH. (2001). J Biol Chem 276: 13505-13508.
46. Wang C, Fu M, Pestell RG. (2004). Methods Mol Biol 241: 207-216.
47. Yaciuk P, Moran E. (1991). Mol Cell Biol 11: 5389-5397.
48. Yuan LW, Gambee JE. (2000). J Biol Chem 275: 40946-40951.
49. Yuan LW, Soh J, Weinstein IB. (2002). Biochem Biophys Acta 1592: 205-211.